Clinical Trials Logo
  1. Home
  2. Adult Acute Myeloid Leukemia
  3. NCT03283228
  4. Details
NCT03283228 Clinical Trial

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia Clinical Trial

Official title:
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT03283228
Other study ID # Myeloid Leukemia Markers
Secondary ID
Status Not yet recruiting
Phase N/A
First received August 27, 2017
Last updated September 12, 2017
Start date December 1, 2017
Est. completion date October 1, 2019

Study information
Verified date September 2017
Source Assiut University
Contact Shaaban Helal, PHD
Phone 01005688567
Email Elhelal2007@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Description:

1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.

2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 30
Est. completion date October 1, 2019
Est. primary completion date December 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

Anew diagnosis cases of adult AML

Exclusion Criteria:

1. Pediatric AML .

2. follow up cases of adult AML

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary CD11b and CD56 marker Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 24 month
See also
  Status Clinical Trial Phase
Completed NCT01146223 - Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Completed NCT01807091 - Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome N/A
Recruiting NCT03114670 - Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT Phase 1
Recruiting NCT05429632 - Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Phase 3
Active, not recruiting NCT03226418 - Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Phase 2
Recruiting NCT05262465 - Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML N/A
Recruiting NCT06329999 - A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML N/A
Completed NCT01484015 - Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Phase 1
Completed NCT01041443 - 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase 1
Completed NCT01251575 - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Phase 2
Recruiting NCT06045819 - Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)
Withdrawn NCT00101140 - Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Phase 2